Evenity (Romosozumab) Cost in South Dakota 2026

What Does Evenity (Romosozumab) Cost in South Dakota in 2026?

The cash-pay price for Evenity (romosozumab) at South Dakota retail pharmacies matches the national manufacturer list price: $1,825 per monthly dose. A full 12-dose course therefore carries a sticker price of roughly $21,900 before any discounts, insurance, or assistance programs.

Amgen and UCB set a single national wholesale acquisition cost for romosozumab. Unlike some specialty drugs that see regional price variation based on pharmacy contracts, South Dakota retail pharmacies consistently reflect that $1,825/month figure in 2026 cash-pay quotes. There is no SD-specific discount built into the supply chain.

Why the Price Is High

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that suppresses bone formation. That mechanism is biologically distinct from bisphosphonates, which simply slow bone resorption. The manufacturing cost of a large-molecule injectable biologic is substantially higher than a generic oral tablet, and that cost passes through to the list price.

What You Actually Pay Depends on Coverage

Very few South Dakota patients pay the full $1,825 out of pocket. The realistic net cost depends on whether you have commercial insurance, Medicare Part D, South Dakota Medicaid, or access to a manufacturer savings program. Each pathway is covered in its own section below.

Does South Dakota Medicaid Cover Evenity (Romosozumab)?

South Dakota Medicaid does not cover Evenity (romosozumab) for severe osteoporosis as of 2026. This means SD Medicaid enrollees cannot use their state benefit to offset the cost of the drug, regardless of fracture history or bone mineral density (BMD) T-score.

Why SD Medicaid Excludes It

State Medicaid programs set their own preferred drug lists (PDLs). South Dakota's PDL prioritizes older, lower-cost osteoporosis therapies, including bisphosphonates such as alendronate and risedronate, and injectable teriparatide. Romosozumab's high acquisition cost and its narrow 12-month treatment window have, so far, kept it off SD's covered list.

Prior Authorization as a Potential Exception

Some Medicaid programs allow prior authorization (PA) requests for non-PDL drugs if a prescriber documents medical necessity and failure of preferred alternatives. South Dakota's Medicaid PA process does not currently have a published pathway for romosozumab approval, but patients and prescribers can submit a PA request and appeal a denial. Success rates for these appeals are low without a documented clinical exception policy in place.

What SD Medicaid Patients Can Do

• Ask your prescriber whether denosumab (Prolia) or zoledronic acid (Reclast) are covered alternatives that achieve meaningful fracture risk reduction.
• Inquire about the Amgen SupportPlus patient assistance program, which has a separate uninsured/underinsured track with income-based eligibility.
• Contact SD Medicaid at (605) 773-3495 to request a written coverage determination so you have documentation for any appeal.

Commercial Insurance Coverage of Evenity in South Dakota

Most commercial health plans sold in South Dakota cover romosozumab, but coverage almost always comes with prior authorization requirements and step-therapy mandates.

Step-Therapy Requirements

Insurers typically require documented failure of or contraindication to at least one bisphosphonate before they approve romosozumab. "Failure" is generally defined as a fragility fracture while on therapy, or continued BMD decline of more than 3% per year at the lumbar spine or total hip despite at least 12 months of adherent bisphosphonate use.

How to Manage a Commercial PA

Your prescribing clinician will need to submit:

1. DXA scan results showing T-score at or below -2.5 (osteoporosis range) or at or below -1.0 with a documented fragility fracture.
2. Evidence of prior bisphosphonate use or a documented contraindication (for example, esophageal dysmotility, renal impairment with GFR <35 mL/min/1.73m²).
3. FRAX 10-year fracture probability, ideally above the National Osteoporosis Foundation threshold of 20% for major osteoporotic fracture or 3% for hip fracture. The NOF's 2022 Clinician's Guide states: "Pharmacologic treatment is recommended when the 10-year probability of a major osteoporotic fracture is ≥20% or the 10-year probability of a hip fracture is ≥3%."

Co-Pay After Insurance Approval

Once approved, commercially insured South Dakota patients typically face a specialty tier co-pay ranging from $150 to $500 per monthly dose, depending on their plan's benefit design. The Amgen/UCB SupportPlus savings card can reduce that co-pay to as low as $0/month for eligible patients (see the savings card section below).

Medicare Part D Coverage of Evenity in South Dakota

Medicare Part D plans classify romosozumab as a specialty-tier drug. In 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D benefits South Dakota seniors who need romosozumab. Once a beneficiary reaches that $2,000 cap, their cost-sharing drops to zero for the remainder of the plan year.

What This Means in Practice

At $1,825/month, a Medicare patient who receives manufacturer-negotiated pricing through their Part D plan could hit the $2,000 annual cap within the first two doses, making months 3 through 12 effectively free at the point of sale. The exact net cost depends on the plan's negotiated rate and low-income subsidy (LIS) status.

Patients with full LIS ("Extra Help") pay only a nominal copay per injection, sometimes as low as $11.20 per dose in 2026.

Important Limitation: Savings Cards Don't Stack with Medicare

The Amgen/UCB SupportPlus savings card is not valid for patients enrolled in Medicare, Medicaid, or any federal health care program. Medicare patients should instead focus on LIS eligibility and their plan's catastrophic coverage threshold.

The Amgen/UCB Evenity SupportPlus Savings Card

For commercially insured South Dakota patients, the SupportPlus program is the single most effective cost-reduction tool available.

How It Works

Eligible patients pay as little as $0 per injection for up to 12 doses. The program covers the gap between insurance reimbursement and any patient cost-share. Enrollment is done online or through the prescribing office; the card is activated at the specialty pharmacy that dispenses the injection (Evenity is typically administered in a clinical setting).

Eligibility Rules

• Patient must have commercial (private) insurance that covers Evenity.
• Patient must be a U.S. Resident.
• Patients enrolled in Medicare Part D, Medicaid, or other federal programs are not eligible.
• An uninsured/underinsured track exists with separate income-based thresholds; patients earning up to 600% of the federal poverty level may qualify.

How to Enroll from South Dakota

Call 1-800-772-6436 or visit the Amgen Assist 360 portal. Your prescribing clinician's office can also enroll on your behalf. South Dakota does not impose any state-level restrictions on manufacturer savings programs.

Is Compounded Romosozumab Legal in South Dakota?

Yes. Compounded romosozumab is available to South Dakota patients through licensed 503A compounding pharmacies. South Dakota follows the federal framework established under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacists to compound drugs for individual patients based on a valid prescription. FDA's 503A guidance is available at the FDA website.

What 503A Means

A 503A pharmacy compounds medications for specific patients under a prescriber's order. The compound is not FDA-approved as a finished drug product, which means it has not undergone the same efficacy and safety testing as branded Evenity. The active pharmaceutical ingredient (API) must be obtained from an FDA-registered supplier.

Cost of Compounded Romosozumab

Compounded romosozumab through a 503A pharmacy can cost significantly less than the $1,825 branded list price. Some SD patients have accessed compounded versions at substantially reduced rates, though pricing varies by pharmacy and formulation.

HealthRX Cost Decision Framework for SD Romosozumab Patients:

| Patient Profile | Recommended First Step | |---|---| | Commercially insured, not Medicare | Apply for SupportPlus savings card; pursue PA | | Medicare Part D, <$2,000 OOP cap reached | Use Part D benefit; check LIS eligibility | | SD Medicaid only | Request PA; consider alternative NOF-approved agents | | Uninsured, income <600% FPL | Apply for Amgen uninsured assistance track | | Uninsured, income above threshold | Consult licensed 503A compounding pharmacy |

Risks and Considerations with Compounded Romosozumab

Compounded biologics carry real risks that branded biologics do not. The FDA has noted that compounded biologics cannot be assumed to be bioequivalent to their reference products because the manufacturing process for large-molecule drugs is integral to the final product's structure and function. Patients considering compounded romosozumab should discuss the following with their clinician:

• Absence of FDA oversight of compounded product sterility, potency, and stability.
• No clinical trial data specifically on compounded romosozumab efficacy.
• Potential immunogenicity differences from the branded product.

This does not mean compounded romosozumab is ineffective. It means the evidentiary bar is lower, and the decision should be made deliberately with a prescriber who understands the tradeoffs.

Can South Dakota Patients Get Evenity via Telehealth?

Yes. South Dakota permits telehealth prescribing of Evenity (romosozumab), provided a valid prescriber-patient relationship exists. The prescriber must be licensed in South Dakota and must conduct an adequate clinical evaluation before issuing a prescription.

What a Valid Telehealth Evaluation Includes

For romosozumab, a clinician conducting a telehealth visit should have access to:

• Recent DXA scan results (typically within the past 12 to 24 months).
• Fracture history, including any vertebral fractures identified on imaging.
• Relevant labs: serum calcium, 25-hydroxyvitamin D, renal function (creatinine, eGFR).
• Current medication list, particularly any antiresorptive history.

A prescriber cannot safely initiate romosozumab without DXA data. Telehealth visits are appropriate for evaluation, prescription, and ongoing monitoring, but the injections themselves must be administered in a clinical setting by a trained healthcare provider.

Why Telehealth Matters for Rural SD Patients

South Dakota has a large rural population with limited access to endocrinologists or rheumatologists who manage complex osteoporosis cases. Telehealth closes that access gap. A SD patient in Mobridge, Pierre, or Spearfish can complete a clinical evaluation via video and have the prescription sent to a local specialty pharmacy without traveling to Sioux Falls or Rapid City.

The Clinical Evidence Behind Romosozumab

Understanding why romosozumab costs what it costs requires understanding what it does. The drug is not interchangeable with bisphosphonates.

ARCH Trial Results

The ARCH trial (N=4,093), published in the New England Journal of Medicine in 2017, compared romosozumab 210 mg monthly for 12 months followed by alendronate versus alendronate alone. At 24 months, the romosozumab-to-alendronate sequence reduced the risk of new vertebral fracture by 48% relative to alendronate alone (6.2% vs. 11.9%, P<0.001). ARCH trial, NEJM 2017.

At 12 months (end of romosozumab phase), the vertebral fracture risk reduction versus alendronate was 73%. Hip fracture risk fell by 38% at 24 months with the sequential regimen.

FRAME Trial Data

The FRAME trial (N=7,180) compared romosozumab against placebo over 12 months, then both groups transitioned to denosumab. Romosozumab reduced new vertebral fractures by 73% at 12 months (0.5% vs. 1.8%, P<0.001) and clinical fractures by 36% (1.6% vs. 2.5%, P<0.001). FRAME trial data is available via PubMed.

FDA-Approved Indication and Boxed Warning

The FDA approved romosozumab in April 2019 for treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure of or intolerance to other osteoporosis therapies. FDA prescribing information.

The label carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab is contraindicated in patients who have had an MI or stroke within the preceding year. This cardiovascular signal emerged from the ARCH trial, where the romosozumab group had a numerically higher rate of serious cardiovascular events than the alendronate group (2.5% vs. 1.9%).

The 2022 American Association of Clinical Endocrinology (AACE) guidelines state: "Romosozumab is recommended for postmenopausal women with very high fracture risk, especially those with prior vertebral fracture, but should be avoided in patients with recent cardiovascular events." AACE 2022 Osteoporosis Guidelines.

Practical Steps to Reduce Your Romosozumab Cost in South Dakota

Getting from a $1,825/month sticker price to an affordable out-of-pocket cost is a process, not a single phone call. Here is the sequence that works for most SD patients.

Step 1: Confirm Your Insurance Status and Coverage Tier

Call the member services number on the back of your insurance card and ask specifically whether romosozumab (NDC prefix 55513) requires prior authorization, what tier it sits on, and what your estimated cost-share will be after PA approval.

Step 2: Work with Your Prescriber on PA Documentation

Your clinician's office will submit the PA. Provide them with your most recent DXA report, any fracture records, and your FRAX score if calculated. Incomplete PA submissions are a leading cause of denial.

Step 3: Apply for the SupportPlus Card Before Your First Injection

The SupportPlus card must be activated before the first dose is dispensed. Enrollment takes 5 to 10 minutes online. Your specialty pharmacy will often help with this step, but do not assume they will initiate it automatically.

Step 4: If Denied or Uninsured, Contact Amgen Assist 360

Amgen Assist 360 (1-800-772-6436) coordinates both the commercial savings card and the patient assistance program for uninsured patients. A case manager will assess your eligibility and, if qualified, can provide the drug at no cost.

Step 5: Discuss 503A Compounding with Your Clinician if All Other Paths Fail

If you are uninsured, ineligible for patient assistance, and facing the full $1,825/month cost, a licensed 503A compounding pharmacy is the remaining option. Bring the FDA safety considerations outlined above to that conversation. Ask the pharmacy for their certificate of analysis (COA) for the active pharmaceutical ingredient and their sterility testing records.

Monitoring Requirements That Affect Total Cost

Romosozumab does not work in isolation. Effective therapy requires baseline and ongoing monitoring that adds to the total treatment cost.

Pre-Treatment Labs

Before starting romosozumab, a prescriber should obtain serum calcium, phosphate, 25-hydroxyvitamin D, and renal function. Hypocalcemia must be corrected before the first injection. Vitamin D deficiency (25-OH-D below 30 ng/mL) affects roughly 40% of adults in northern-latitude states, and SD patients should anticipate needing supplementation. NEJM evidence on vitamin D and bone health.

DXA Scans

A follow-up DXA at 12 months (end of romosozumab course) confirms treatment response and guides the transition agent. Medicare covers DXA every 24 months for established osteoporosis; some commercial plans cover it annually for patients on active bone-building therapy. The out-of-pocket cost of a DXA scan in South Dakota ranges from $150 to $350 without insurance.

Transition Therapy

After 12 months of romosozumab, patients must transition to an antiresorptive agent to preserve the bone gained. Denosumab (Prolia) or a bisphosphonate are the standard options. Failing to transition results in rapid bone loss and fracture risk returning toward baseline within 12 to 24 months. The cost of transition therapy is a separate expense that patients should budget for before starting romosozumab.